Comorbidities in RA: Focus on Difficult-to-Treat Disease
Sep 26, 2023
Recent News
Patients with RA have on average two additional other clinical conditions and research shows that these accumulate over time and with longer disease duration. The presence of comorbidities naturally complicates treatment choice, patient adherence to medication and patient outcomes, increasing also the risk of making RA ‘difficult-to-treat’.Read Article
Join us for our final webinar this month, DMARD Choices & Changes. The panel will discuss rheumatologists' choices in choosing 2nd line & 3rd line DMARD therapy, when or if to wean/de-escalate DMARDs and how to proceed with restarting therapy when needed.
https://t.co/FRAHiWU1Lt https://t.co/3acv8EXjzQ
Sep 26, 2023
When do you consider switching vs cycling in patients with RA after first TNFi failure?
Watch Dr. Roy Fleischmann and Dr. Janet Pope discuss treatment options for patients with RA following first TNFi failure. Sponsored by AbbVie US Medical Affairs.
https://t.co/6d7i3OdMwf https://t.co/T5T66rakTQ
Sep 26, 2023
RA QD Clinic: RA with Eye Problems
Features Dr. Michael Putman (Milwaukee, WI) RA patient presents with new, chronic eye redness - what are the possibilities? RA QD Clinics are video vignettes with lessons from the clinic.
https://t.co/2dWzdE1KnJ https://t.co/YzMzvt5jg2
Sep 26, 2023
Cognitive-behavioral Therapy Lessens Fibromyalgia Pain
In a recent clinical trial of patients with fibromyalgia, CBT, was superior to a matched education treatment in reducing the interfering effects of pain and other aspects of fibromyalgia daily.
https://t.co/fq5RTKAY3t https://t.co/AAjh77BW0Q
Sep 26, 2023
Long-term Safety of a JAKi in Patients with RA With up to 6.5 Years of Exposure
View this poster on the long-term integrated safety data with a JAKi in patients with RA from 6 clinical studies. Sponsored by AbbVie US Medical Affairs
https://t.co/cU4AIeb2B8 https://t.co/EBPXdvMQu8
Sep 26, 2023
Multicentre retrospective study of 92 pts with paraneoplastic arthritis (PA), found PA seen more w/ hematological malignancies (lymphomas 26%) and solid malignancy (most were lung CA 41.5%). PA pts more likely to be CCP+ (P=0.014). https://t.co/GVBwIRDYJD https://t.co/JBXJPlg5M9
Sep 26, 2023
Advice on Multi-Drug Failures in RA
Sep 25, 2023
What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics? In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.
As many of us struggle with multi-drug failures in RA, I reached out to the RA therapy mavens, trialists and teachers and asked, “Can you write a few words on Multi-drug failures in RA.”
Read Article
What Changed FDA's Mind About Ilaris for Gout?
The FDA quietly approved the interleukin (IL)-1 inhibitor canakinumab (Ilaris) for gout 10 days ago, with no announcement from either the agency or the drug's manufacturer, Novartis.
https://t.co/9vqQxdmkzS https://t.co/KFoy7SX59Z
Sep 25, 2023
Update on Anti-Drug Antibodies and Therapeutic Drug Monitoring #RA
https://t.co/w1GKoDvvKS https://t.co/hyBFcEvImI
Sep 25, 2023
Korean retrospective cohort study betw 4/20-11/22 shows COVID infx assoc w/ increased risk of autoimmune disease; BUT 2 doses of COVID-19 vaccine was assoc w/ decrease risk of pemphigoid, Graves, APL syndrome, ITP, SLE, autoimmune arthritis https://t.co/vzBEcalUL9 https://t.co/P4yWSvjTJL
Sep 25, 2023
Large cohort study of hospitalized #AS shows that the leading cause of death in AS were cardiovascular, infectious, respiratory, & traumatic. Mortality risk was signif assoc w/ Elixhauser comorbidity index, CHF, & renal dz. NSAIDs did not increase risk https://t.co/6nlDxvO8pO https://t.co/V3hZq5xQ6Q
Sep 25, 2023
Great full-read review of advances in osteoarthritis #OA in the last 5 years (2018-2023) by Dr. Berenbaum (Ann Rheum Dis) - addressing Epidemiology, Biomarkers and Treatments https://t.co/roONipkOVh https://t.co/EbsKHsmEcY
Sep 25, 2023
Systematic review of #RA RCTs shows that the number needed to treat (NNT) for 2nd-generation biologics success is 4-6 to achieve one ACR50 response, while withdrawals due to adverse events were few and non-significant https://t.co/sbU40aTvHN https://t.co/9Ce3LbRwmg
Sep 25, 2023
Assessing Cardiovascular Risks: The Responsibility of the Rheumatologist
In 2016, EULAR posted recommendations for the management of cardiovascular (CV) risks in patients with rheumatoid arthritis (#RA) and other inflammatory joint diseases (IJ D)1.
https://t.co/OhE44GkvMB https://t.co/XhoTah7PTp
Sep 24, 2023
Machine Learning May Diagnose Psoriatic Arthritis Earlier
A machine learning approach was applied to two different population cohorts and was shown to be effective at the early identification of undiagnosed psoriatic arthritis (PsA).
https://t.co/ecAF5OTgfr https://t.co/9R2ZZH3I7j
Sep 24, 2023
#RA QD Clinic: Induced inflammatory arthritis
Dr. David Liew, a rheumatologist in Melbourne, Australia, discusses induced inflammatory arthritis as part of RheumNow's Hard Decisions in RA campaign
https://t.co/Wble2GZqD4
@drdavidliew https://t.co/kcwCw4JPB8
Sep 24, 2023
Study compared 491SLE pts tested for ANCA Abs w/ 171 ANCA-associated vasculitis (AAV) pts. 46 SLE pts were ANCA+. ANCA-positive LN have worse baseline renal function and lower protein remission rates . https://t.co/jlikQlW9OR https://t.co/yMcULGsnTu
Sep 24, 2023
RheumNow Podcast with Special Guest Dr. Michael Weinblatt (9.22.2023)
Sep 22, 2023
Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions.
Read Article
Ginger may reduce Netosis, AutoAb & thrombosis in SLE. 6-gingerol is the most bioactive component of ginger root. 6-gingerol attenuates neutrophil extracellular trap release in murine models & partially dependenet on phosphodiesterase inhibition. https://t.co/urlmWFmdSl https://t.co/aRIOZcgSub
Sep 22, 2023
#RA QD Clinic: Cardiovascular Risk and RA
Features Dr. Kathryn Dao (Dallas, TX) A high Risk RA patients - how to manage the cardiovascular risks.
https://t.co/jc3fvaP9l3 https://t.co/tYswHxqnNX
Sep 22, 2023
From the blog
With the increasing development and use of new biologics and oral targeted therapies to treat RA and other immune mediated inflammatory diseases, an awareness of infection risk and prevention has become of increasing interest as well. While our patients may be susceptible to many different types of infections depending on immunosuppressive regimen, age and co-morbidities, I’ll highlight a few of the “usual suspects”.
Read Post
Cancer is the most difficult DMARD risk to discuss with patients. Few warnings could scare people away from a drug faster than the words “may increase risk of cancer,” yet the risks (even when substantiated) have all been low and may be counterbalanced by the benefits of disease control.
Read Post
In 2016, EULAR posted recommendations for the management of cardiovascular risks in patients with rheumatoid arthritis and other inflammatory joint diseases. Three overarching principles emerged, but one caught my attention: “the rheumatologist is responsible for CV disease risk management.” It leaves no room for interpretation.
Read Post
Podcasts
RheumNow Podcast – with Special Guest Dr. Michael Weinblatt (9.22.2023)Sep 22, 2023
RA QD Clinics - Week 3Sep 22, 2023
TNR - Methotrexate DecisionsSep 20, 2023-
RA QD Clinics - Week 2Sep 18, 2023
Therapeutic Updates
Perspectives: The Future of RA
Sponsored by RheumNow
Sep 01, 2023
Drs. Iain McInnes and Gerd Burmester discuss their perspectives on the future management of people with RA. These and more debates and perspectives on Hard Decisions in RA now available.
Read Post
When do you consider switching vs cycling in patients with RA after first TNFi failure?
Sponsored by AbbVie Medical Affairs
Sep 01, 2023
Watch rheumatologists Dr. Roy Fleischmann and Dr. Janet Pope discuss treatment options for patients with RA who have failed a TNFi. The experts consider switching to an alternate MOA vs cycling to another TNFi.
Read Post
Poster Hall
